R. Rangwala
Merck & Co., Inc., Rahway, NJ, USA (United States) · 1 works · 5 citations · h-index 1
Top works
437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%